Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Carboplatin in Triple Negative Breast Cancer
NCT01372579Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- Aug 2011
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in triple-negative breast cancer (TNBC), sponsored by Northwestern University. Status: unknown.
02
Drugs
eribulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01372579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01372579.